Voyager Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended March31,2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period from ______ to ______Commission file number: 001-37625 Voyager Therapeutics, Inc.(Exact name of Registrant as specified in its charter) Delaware(State or other jurisdiction ofincorporation or organization) (857) 259-5340(Registrant’s telephone number, including area code) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes⌧No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes⌧No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☒Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of April 30, 2026, was 60,421,287. Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantialrisks and uncertainties. All statements other than statements of historical facts contained in this QuarterlyReport on Form 10-Q, including statements regarding our strategy, future operations, future financialposition, future revenue, projected costs, prospects, plans, objectives of management and expected marketgrowth, are forward-looking statements. These statements involve known and unknown risks, uncertaintiesand other important factors that may cause our actual results, performance or achievements to bematerially different from any future results, performance or achievements expressed or implied by theforward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”“predict,” “project,” “target,” “potential,” “contemplate,” “anticipate,” “goals,” “will,” “would,” “could,”“should,” “continue,” and similar expressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words. These forward-lookingstatements include, among other things, statements about: ●our plans to develop and commercialize our proprietary adeno-associated virus, or AAV, genetherapy, antibody, non-viral therapeutic, and small molecule product candidates;●our ability to continue to develop our proprietary gene therapy platform technologies,including our TRACERTM(Tropism Redirection of AAV by Cell-type-specific Expressionof RNA) discovery platform, our non-viral therapeutics platform, including VOYAGERNEUROSHUTTLETM, and our proprietary antibody, small molecule, gene therapy, shuttledor vectorized antibody, and non-viral therapeutic programs;●our ability to identify and optimize product candidates, proprietary AAV capsids, and non-viral blood-brain-barrier shuttles;●our strategic collaborations and licensing agreements with, and funding from, ourcollaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG and ourlicensee Alexion, AstraZeneca Rare Disease (successor-in-interest to former licensee PfizerInc.);●our collaboration with Transition Bio, Inc. to advance small molecules targeting TDP-43 totreat amyotrophic lateral sclerosis and frontotemporal dementia with TDP-43 pathology;●our ongoing and planned clinical trials, preclinical development efforts, related timelines andstudies, including our plans to generate initial data from the Phase 1 multiple ascending doseclinical trial of VY7523 in early Alzheimer’s disease patients in the second half of 2026,complete the investigational new drug, or IND, application process for the VY1706 programin the second quarter of 2026, and, subject to successful IND clearance,